Medical Doctor Program year 2025 Reported 2019–2025 Source: CMS Open Payments, 2026 publication

Richard Seeger

Ophthalmology Webster, NY Medical Doctor

NPI 1083681001 CMS profile 94635

1015 Ridge Rd, Webster, NY 14580

Open in the dashboard

General payments

$867

14 records reported · program years 2019–2025

Research payments

$0

Paid to them · None reported · program years 2019–2025

Ownership & investment interest

$0

None reported

Through program year 2025, Richard Seeger of Webster, NY is reported in the CMS Open Payments database as having received $867 across 14 general payments and $0 in research payments paid to them.

No combined total General, research and ownership are kept apart. Each is reported under its own rules, and ownership is not money that moved at all but the value of a stake held. A meal, a clinical trial grant and a shareholding do not add up to anything meaningful, so this site does not add them.

General payments for this record sit in the 41st percentile of Ophthalmology profiles with reported payments. Percentile describes the distribution, not the conduct.

By program year

5 rows
Year Kind Relative to this record's peak year Amount Records
2025 General $164 5
2023 General $306 3
2022 General $31 1
2021 General $114 2
2019 General $252 3

Beside peers

Year by year, beside peers General payments · among profiles paid that year
  • Richard Seeger
  • Ophthalmology median
  • Middle half of Ophthalmology
  • National median

In program year 2025, general payments to Richard Seeger were reported at $164. Among 13,034 Ophthalmology profiles paid that year, the median was $384 and the middle half received between $136 and $917.

Show as a table
Year Richard Seeger Ophthalmology median Middle half National median
2019 $252 $258 $104–$655 $163
2020 $0 $126 $45–$321 $114
2021 $114 $205 $76–$534 $132
2022 $31 $266 $100–$678 $149
2023 $306 $308 $117–$745 $160
2024 $0 $340 $127–$846 $164
2025 $164 $384 $136–$917 $169

Breakdown

Who paid General payments · program years 2019–2025
  1. New World Medical,Inc. $177 1 payment
  2. Amgen Inc. $164 5 payments
  3. Allergan Inc. $144 3 payments
  4. Bausch & Lomb, a division of Bausch Health US, LLC $125 1 payment
  5. Sight Sciences, Inc. $116 2 payments
  6. AbbVie, Inc. $110 1 payment
  7. Johnson & Johnson Surgical Vision, Inc. $31 1 payment

Every payment, record by record

What the payments were for General payments · program years 2019–2025
  1. Food and Beverage $867 14 payments
Products named General payments · program years 2019–2025
  1. TEPEZZA $164 5 payments
  2. ENVISTA $125 1 payment
  3. AMVISC PLUS $125 1 payment
  4. XEN $125 1 payment
  5. XEN GLAUCOMA TREATMENT SYSTEM Eye Care $110 1 payment
  6. OMNI(R) SURGICAL SYSTEM (US) $97 1 payment
  7. VERITAS Vision System $31 1 payment
  8. OMNI SURGICAL SYSTEM $19 1 payment
  9. XEN GLAUCOMA TREATMENT SYSTEM Glaucoma $17 1 payment
  10. LUMIGAN $2 1 payment

A payment can name more than one product, so these amounts overlap and do not add up to the general-payment figure.

Prescribing to Medicare patients

Part D · data year 2024 · 28 drugs

Part D claims

4,407

Median for Ophthalmology: 891

Drug cost

$369,135

Median for Ophthalmology: $68,233

Branded share of claims

25.9%

Median for Ophthalmology: 29.7%

Drugs this doctor was counted under in Medicare Part D 2024, by drug cost
Drug Type Relative to their largest Claims Drug cost
Rhopressa Netarsudil Mesylate Brand 171 $73,766
Lumigan Bimatoprost Brand 126 $66,781
Vyzulta Latanoprostene Bunod Brand 142 $36,774
Rocklatan Netarsudil Mesylat/Latanoprost Brand 77 $29,897
Restasis Cyclosporine Brand 18 $29,054
Cyclosporine Generic 30 $22,029
Prednisolone Acetate Generic 371 $15,750
Brimonidine Tartrate Generic 311 $14,504
Latanoprost Generic 1,280 $14,367
Brimonidine Tartrate-Timolol Brimonidine Tartrate/Timolol Brand 55 $12,149

The 10 drugs with the highest cost, of 28 counted.

Drug cost is what was paid for the drugs at the pharmacy — by Medicare, the patient and others — and is not money to the prescriber. Medicare Part D only: drugs dispensed to Medicare beneficiaries. A drug with fewer than 11 claims for this prescriber is not published, so a missing drug does not mean zero. The medians are for the 18,260 Part D prescribers listed as Ophthalmology; they describe a distribution and say nothing about conduct.

Billing to Medicare

Part B · data year 2024 · 29 billing codes

Paid by Medicare

$106,284

Medicare's payments for the services billed

Medicare patients

276

Average age 79

Services billed

894

164 women, 112 men among their patients

Share of this provider's Medicare patients with each condition
Condition among their Medicare patients Relative to the most common Share of patients
High blood pressure 75%
Arthritis 47%
Diabetes 36%
Ischemic heart disease 24%
Chronic kidney disease 21%
Atrial fibrillation 20%
Depression 20%
Osteoporosis 18%

Medicare Part B only: services billed to Medicare. Rows covering fewer than 11 beneficiaries are not published. Only drugs given in the clinic are itemised here; the rest of what this provider billed is in the total above.

Records

14 reported

Every payment, record by record

Date, company, amount, what it was for and the product named — filter by year, kind and company, or download as CSV.

Other Ophthalmology in New York

Related records

What this means

U.S. law requires drug and medical device manufacturers to report payments and transfers of value they make to physicians and teaching hospitals. The Centers for Medicare & Medicaid Services publishes that record each year. This page shows what was reported about this person, and nothing else.

An ownership interest is different from the other two. It is not a payment: it is a stake — shares, options, a partnership holding — that a physician or an immediate family member held in a manufacturer during that year. The figure shown is what the stake was reported to be worth.

Research payments frequently pass through a clinician to the institution running a trial, and rarely represent personal income. They should be read differently from general payments.

Provenance

Source: CMS Open Payments · through program year 2025

Data current to program year 2025, from CMS's 2026 publication.

We reproduce what manufacturers reported. We do not verify, edit or correct the underlying records.

A payment record is not evidence of wrongdoing. Financial relationships between industry and medicine are legal, common and often necessary for research. Who Paid My Doc reports what was disclosed; it does not judge it.

Who Paid My Doc is independent and is not affiliated with, endorsed by or sponsored by CMS or any U.S. government agency. It is not a consumer reporting agency and this is not a consumer report; do not use it for decisions covered by the Fair Credit Reporting Act.

How to dispute or correct a record